查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1861934

生物製药生产耗材检测市场按产品类型、检测类型、技术、应用和最终用户划分 - 全球预测（2025-2032 年）

Biopharmaceuticals Manufacturing Consumables Testing Market by Product Type, Testing Type, Technology, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，生物製药生产耗材测试市场将成长至 15.524 亿美元，复合年增长率为 12.12%。

关键市场统计数据
基准年 2024 6.2139亿美元
预计年份：2025年 6.9693亿美元
预测年份 2032 15.524亿美元
复合年增长率 (%) 12.12%

了解耗材检测在生物製药生产中的基础性作用，以及产品类型和检测方法如何支援製程完整性。

随着生物製药生产的不断发展，耗材检测已成为品质保证、製程效率和法规遵循的关键环节。本执行摘要重点分析了从上游工程到下游整个生命週期中的耗材检测实践，着重阐述了用于保障产品安全和製程完整性的材料和方法。摘要首先检视了层析法介质、过滤耗材、取样组件、一次性使用袋和组件以及管路和接头等产品类型，并展示了这些要素如何融入分析和放行前检测体系。此外，概要也强调了微生物附着量、内毒素、pH值和无菌性检测等检测方法在生产控制策略和批次管理中发挥的关键作用。

要认识到，先进分析平台的普及、一次性产品的采用以及日益严格的监管正在迅速重新定义耗材测试和对供应商的期望。

由于技术应用、监管日益严格以及供应链重组，生物製药耗材检测领域正在经历变革。分析平台的进步正在重塑製造商检验和监控耗材的方式。即时PCR和质谱分析能够早期检测污染物，而ELISA和流式细胞技术则继续为关键的放行检测流程提供支援。同时，一次性包装袋、组件和整合管路系统的普及，使得可萃取物和萃取物评估、无菌保证以及相容性测试的重要性日益凸显，迫使供应商在材料和灭菌方法方面进行创新。

评估近期美国关税调整如何重塑耗材测试供应链的筹资策略、合格时间表和总成本考量。

美国近期关税政策的变化为耗材测试组件的采购计画和供应商策略带来了新的变数。关税调整影响进口层析法树脂、过滤介质和专用一次性组件，进而影响最终到岸成本结构和前置作业时间。为此，许多製造商和供应商正在重新评估采购区域，修订库存政策，并加快近岸外包和双重采购策略，以降低成本波动的风险。这些调整通常会导致更长的资格认证週期，因为替代材料和供应商需要进行适用性和性能检验。

了解产品类型、测试方法、分析技术、应用领域和最终用户画像如何共同决定测试优先事项和供应商选择。

详细的細項分析表明，产品类型、测试类型、技术、应用和最终用户各自驱动耗材测试生态系统中不同的需求和策略性应对措施。在产品类型维度上，层析法介质、过滤耗材、采样组件、一次性使用袋和组件以及管路和连接器构成了实验室产品组合，这些产品组合必须经过相容性和性能检验。具体而言，层析法介质包括亲和性和树脂、离子交换树脂、Protein A 树脂和尺寸排阻介质，每种介质都有不同的清洁、再生和结合特性，这些特性会影响测试频率和方法。过滤耗材包括滤芯过滤器、深度过滤器和薄膜过滤器，它们的选择会影响无菌保证方法和颗粒监测通讯协定。一次性使用袋和组件包括生物反应器袋、混合袋和储存袋，它们的材料选择会影响可萃取物和可萃取物测试的范围。

探讨不同地区在製造业密度、法规结构和供应商生态系统的差异如何影响各地区的采购、验证和测试策略。

区域趋势对生物製造中耗材检测的可用性、成本和监管要求产生了重大影响。在美洲，先进的製造地和一体化的供应链支援一次性系统和先进分析平台的快速普及，而监管机构对严格污染控制和产品可追溯性的重视正在塑造检测要求。放眼东方，欧洲、中东和非洲地区（EMEA）呈现出多元化的格局，统一的法规结构与区域差异并存，迫使製造商在采用标准化检测通讯协定的同时，还要应对特定区域的认证和进口流程。在亚太地区，不断提升的本地製造能力以及对生物相似药和契约製造的高度重视，正在推动对高通量检测流程和区域供应商生态系统的投资，从而实现具有竞争力的前置作业时间和价格。

识别供应商和服务供应商之间的策略差异化因素，例如材料创新、自动化、可追溯性和区域製造韧性。

产业参与者涵盖了从专业耗材和分析设备供应商到垂直整合供应商和第三方检测实验室等各类企业，从而形成了复杂的竞争格局。主要企业正投资于材料科学创新，以减少萃取物和浸出物；投资于无菌和微生物附着量测试自动化，以提高检测效率；并投资于数位化可追溯性解决方案，以简化文件记录和供应商合格。耗材製造商和分析平台供应商之间的合作也不断加强，透过提供预先认证组件和简化的工作流程，减轻终端用户的验证负担。同时，合约检测机构也在拓展服务范围，以支援分散式製造，包括整合样品管理、快速週转测试和法规报告。

实施品质和供应弹性策略，将供应商选择、自动化分析、采购多元化和供应商协作开发结合。

产业领导者必须采取协调一致的策略，同时应对品质、供应韧性和成本压力。首先，建立严格的供应商资格认证体系，包括多阶段效能测试、原料来源验证和合约服务水准预期，以减少对单一供应商的依赖。其次，优先投资分析自动化和资料集成，以缩短测试週期并改善决策。这包括将ELISA、PCR和质谱分析的工作流程与实验室资讯管理系统相协调，从而实现快速趋势分析。第三，透过对替代供应商和区域合作伙伴进行资格认证，促进采购多元化，并建立紧急库存和灵活的合约结构，以应对关税和物流中断等情况。

我们采用混合方法研究途径，结合技术文献综述、专家访谈、供应商文件和真实案例检验。

本执行摘要的调查方法整合了第一手和第二手资料，并经过同行检验，以确保其稳健性和相关性。首先，透过对技术文献、法规指南和产品规格的系统性回顾，建立了对耗材和测试技术的基本理解，包括层析法介质、过滤类型、一次性组件和分析平台之间的功能差异。其次，透过与品管人员、采购专家和实验室主任的访谈，获得了关于供应商选择标准、测试瓶颈以及应对关税相关供应中断的实际观点。这些访谈辅以供应商产品文件和公开的法规文件，以对有关性能特征和合检验方法的说法进行三角验证。

摘要，要确保可靠且合规的生物製药生产，策略上需要协调测试流程、供应商合格和分析能力。

总之，生物製药生产中的耗材检测是一项策略性职能，它直接影响产品品质、营运效率和监管合规性。不断发展的技术、不断变化的采购地域以及日益严格的监管，都要求製造商积极主动地进行供应商资质合格、投资分析能力建设并製定稳健的供应策略。透过专注于材料的适用性、方法的稳健性和供应商的透明度，企业可以缩短产品放行时间、减少批次不合格率并维护监管机构的信任。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合一次性感测器技术，用于即时监测关键生物过程程式参数
  • 在耗材性能检验中引入人工智慧驱动的预测品质分析
  • 新一代无菌检测：利用快速微生物检测平台
  • 采用具有高吸附能力的先进聚合物过滤器进行单株抗体纯化过程
  • 标准化一次性生物製程组件的可萃取物和可浸出物测试通讯协定
  • 开发用于製程控制的可自订一次性组件，该组件带有在线连续压力和电导率感测器
  • 为实现耗材测试工作流程的可追溯性和合规性，转向云端基础的资料管理平台
  • 推出萤光的快速检测一次性细胞培养基袋中微生物附着量的方法
  • 生物加工环境中耗材选择与处置策略中生命週期永续性指标的重要性

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 生物製药生产耗材检测市场（依产品类型划分）

  • 层析法介质
    • 亲和性和树脂
    • 离子交换树脂
    • 蛋白A树脂
    • 尺寸排阻介质
  • 过滤耗材
    • 滤芯过滤器
    • 深度过滤器
    • 薄膜过滤器
  • 采样组件
  • 一次性包装袋和组件
    • 生物反应器袋
    • 喜忧参半
    • 收纳袋
  • 管材和连接器

9. 生物製药生产耗材检测市场（依检测类型划分）

  • 微生物附着量检测
  • 内毒素试验
  • pH测试
  • 无菌测试
    • 直接接种试验
    • 膜过滤试验

第十章 生物製药生产耗材检测市场（依技术划分）

  • ELISA
    • 竞争性ELISA
    • 间接ELISA
    • 夹心ELISA
  • 流式细胞技术
  • 质谱分析
  • 即时PCR

第十一章 生物製药生产耗材检测市场（依应用领域划分）

  • 细胞培养监测
  • 蛋白质纯化
    • 亲和层析法
    • 离子交换层析法
    • 尺寸排阻层析法
  • 病毒清除

第十二章 生物製药生产耗材检测市场（依最终用户划分）

  • 学术研究机构
  • 生物製药公司
    • 生物相似药生产商
    • 大型製药企业
    • 中型製药公司
  • 契约製造组织
  • 受託研究机构

第十三章 生物製药生产耗材检测市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 生物製药生产耗材检测市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国生物製药生产耗材检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Merck KGaA
    • Sartorius AG
    • Corning Incorporated
    • Agilent Technologies Inc.
    • Lonza Group AG
    • PerkinElmer Inc.
    • Tecan Group Ltd
    • Repligen Corporation
Product Code: MRR-521BAA36EA7E

The Biopharmaceuticals Manufacturing Consumables Testing Market is projected to grow by USD 1,552.40 million at a CAGR of 12.12% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 621.39 million
Estimated Year [2025] USD 696.93 million
Forecast Year [2032] USD 1,552.40 million
CAGR (%) 12.12%

Understand the foundational role of consumables testing in biologics manufacturing and how product categories and testing modalities underpin process integrity

The evolution of biopharmaceutical manufacturing has placed consumables testing at the intersection of quality assurance, process efficiency, and regulatory compliance. This executive summary introduces a focused analysis of consumables testing practices across the upstream and downstream lifecycle, emphasizing materials and methods used to protect product safety and process integrity. Beginning with an exploration of product categories such as chromatography media, filtration consumables, sampling assemblies, single-use bags and assemblies, and tubing and connectors, the content frames how these elements integrate into analytical and release testing paradigms. It also highlights the critical role of testing modalities-bioburden, endotoxin, pH, and sterility assays-tied to manufacturing control strategies and batch disposition.

As manufacturing models shift toward single-use technologies, outsourced processing, and high-throughput biologics production, consumables testing increasingly determines the velocity of scale-up and the robustness of regulatory submissions. Therefore, this introduction establishes the foundation for deeper sections by clarifying the relationships between product families, testing types, and analytical technologies including ELISA variants, flow cytometry, mass spectrometry, and real-time PCR. The aim is to orient decision-makers to the primary levers that influence quality outcomes, supplier selection, and laboratory capability investments, enabling an immediate appreciation of downstream operational imperatives.

Recognize the convergence of advanced analytical platforms, single-use adoption, and regulatory tightening that is rapidly redefining consumables testing and supplier expectations

The biopharmaceutical consumables testing landscape is undergoing transformative shifts driven by technology adoption, regulatory tightening, and supply chain reconfiguration. Advances in analytical platforms are reshaping how manufacturers validate and monitor consumables, with real-time PCR and mass spectrometry enabling earlier detection of contaminants while ELISA and flow cytometry continue to support critical release testing workflows. At the same time, the move toward single-use bags, assemblies, and integrated tubing systems has increased the importance of extractables and leachables assessment, sterility assurance, and compatibility testing, prompting suppliers to innovate materials and sterilization approaches.

Concurrently, regulatory authorities globally are strengthening expectations for contamination control strategies and documentation rigor, elevating the importance of standardized testing protocols and traceable supply chains. Outsourcing models are evolving as contract manufacturing organizations and contract research organizations scale capabilities, creating demand for testing services optimized for throughput and regulatory defensibility. Taken together, these shifts require manufacturers to adopt a layered approach to risk management that couples advanced analytical techniques with robust vendor qualification, while investing in cross-functional teams capable of translating test data into process decisions.

Assess how recent United States tariff changes are reshaping sourcing strategies, qualification timelines, and total cost considerations for consumables testing supply chains

Recent tariff developments in the United States have introduced new variables into procurement planning and supplier strategy for consumables testing components. Tariff adjustments affect imported chromatography resins, filtration media, and specialized single-use assemblies, which in turn influence landed cost structures and lead time dynamics. In response, many manufacturers and suppliers are reassessing sourcing geographies, revisiting inventory policies, and accelerating nearshoring or dual-sourcing strategies to mitigate exposure to sudden cost shifts. These adjustments often cascade into longer qualification timelines as alternate materials and suppliers undergo compatibility and performance validation.

Importantly, tariff-driven cost pressures are not limited to direct purchasables; they extend to ancillary services, packaging, and logistics that support laboratory operations. Consequently, procurement teams are enhancing total-cost-of-ownership evaluations, prioritizing suppliers with resilient logistics networks and regional manufacturing footprints. Meanwhile, research and development groups are exploring material substitutions and process adjustments that reduce dependence on tariff-affected items without compromising critical quality attributes. Overall, the cumulative impact of tariffs has prompted a renewed emphasis on sourcing flexibility, supplier collaboration, and upfront risk assessment to preserve continuity of testing and release activities.

Unpack how product categories, testing modalities, analytical technologies, application areas, and end user profiles collectively determine testing priorities and supplier selection

A nuanced segmentation analysis reveals that product type, testing type, technology, application, and end user each drive distinct needs and strategic responses across the consumables testing ecosystem. Within the product type dimension, chromatography media, filtration consumables, sampling assemblies, single-use bags and assemblies, and tubing and connectors define portfolios that laboratories must validate for compatibility and performance. Chromatography media in particular spans affinity resins, ion exchange resins, protein A resins, and size exclusion media, each with different cleaning, regeneration, and binding characteristics that inform testing frequency and methods. Filtration consumables encompass cartridge filters, depth filters, and membrane filters, and their selection affects sterility assurance practices and particulate monitoring protocols. Single-use bags and assemblies include bioreactor bags, mixing bags, and storage bags, and their material choices influence extractables and leachables testing scope.

Testing type segmentation distinguishes between bioburden testing, endotoxin testing, pH testing, and sterility testing, recognizing that sterility testing itself often requires either direct inoculation or membrane filtration approaches that carry divergent sample handling and incubation requirements. Technology segmentation highlights how ELISA modalities, flow cytometry, mass spectrometry, and real-time PCR are used across testing workflows, noting that ELISA can be deployed as competitive, indirect, or sandwich formats depending on analyte and sensitivity needs. Application segmentation clarifies that cell culture monitoring, protein purification, and viral clearance each place different demands on consumable performance; protein purification techniques such as affinity chromatography, ion exchange chromatography, and size exclusion chromatography interact directly with media selection and downstream analytical checks. Finally, end users across academic and research institutes, biopharmaceutical companies, contract manufacturing organizations, and contract research organizations present varying procurement cycles, validation rigor, and volume needs, while biopharmaceutical companies themselves include biosimilar manufacturers, large pharma, and mid-size pharma with discrete regulatory risk appetites and supply chain priorities. Synthesizing these segmentation layers enables targeted strategies for supplier selection, testing protocol design, and laboratory capability investments that align with specific operational and regulatory contexts.

Explore how geographic differences in manufacturing density, regulatory frameworks, and supplier ecosystems shape procurement, validation, and testing strategies across regions

Regional dynamics exert a material influence on the availability, cost, and regulatory expectations surrounding consumables testing in biomanufacturing. In the Americas, advanced manufacturing hubs and integrated supply chains support rapid adoption of single-use systems and sophisticated analytical platforms, while regulatory agencies emphasize rigorous contamination control and product traceability that shape testing requirements. Moving eastward, Europe, the Middle East, and Africa present a heterogeneous landscape in which harmonized regulatory frameworks coexist with regional variability, prompting manufacturers to adopt standardized testing protocols while accommodating localized certification and import processes. In Asia-Pacific, rising local manufacturing capacity and a strong emphasis on biosimilars and contract manufacturing have driven investments in high-throughput testing workflows and regional supplier ecosystems that can offer competitive lead times and pricing.

Across these regions, differences in logistics infrastructure, customs procedures, and local supplier maturity lead manufacturers to tailor sourcing strategies that balance cost, lead time, and qualification burden. For global programs, leveraging regional distribution partners and aligning laboratory methods to meet cross-border regulatory expectations are essential strategies to ensure consistent quality outcomes. In short, geographic context matters not only for procurement but also for the design of validation studies, the selection of analytical technologies, and the prioritization of investments in local testing capacity.

Identify the strategic differentiators among suppliers and service providers including material innovation, automation, traceability, and regional manufacturing resilience

Industry participants range from specialized consumables and analytical equipment providers to vertically integrated suppliers and third-party testing laboratories, creating a complex competitive landscape. Leading companies are investing in material science innovations to reduce extractables and leachables, in automation of sterility and bioburden assays to increase throughput, and in digital traceability solutions to simplify documentation and supplier qualification. Partnerships between consumable manufacturers and analytical platform vendors are also emerging, aimed at delivering pre-qualified assemblies and simplified workflows that reduce the validation burden for end users. At the same time, contract testing organizations are expanding service offerings to include integrated sample management, rapid turnaround testing, and regulatory-compliant reporting to support decentralized manufacturing footprints.

As a result, differentiation is increasingly driven by a combination of technical support, regulatory know-how, and supply chain reliability rather than on price alone. Companies that can demonstrate robust quality systems, transparent material provenance, and flexible regional manufacturing capacity are better positioned to capture long-term relationships with biopharmaceutical developers and production sites. For procurement teams, evaluating potential partners requires assessing not only product performance but also the supplier's ability to collaborate on method transfer, participate in problem-solving during scale-up, and maintain continuity under geopolitical and logistical stressors.

Adopt an integrated quality and supply resilience playbook that combines vendor qualification, analytical automation, sourcing diversification, and collaborative supplier development

Industry leaders must adopt coordinated strategies that address quality, supply resilience, and cost pressures simultaneously. First, establish rigorous vendor qualification programs that incorporate multi-tiered performance testing, material provenance checks, and contractual service-level expectations to reduce reliance on single sources. Second, prioritize investments in analytical automation and data integration to shorten testing cycles and improve decision-making; this includes harmonizing ELISA, PCR, and mass spectrometry workflows with laboratory information management systems to enable rapid trend analysis. Third, pursue sourcing diversification by qualifying alternative suppliers and regional partners while developing contingency inventories and flexible contracting arrangements to buffer against tariff and logistics disruptions.

In parallel, organizations should accelerate collaborative initiatives with suppliers to co-develop pre-qualified assemblies and test-ready components that reduce validation time. Strengthening cross-functional teams that bring together procurement, quality, and R&D will improve responsiveness during scale-up and technology transfer. Finally, embed continuous improvement by monitoring performance metrics tied to testing throughput, supplier delivery consistency, and nonconformance rates, and use those metrics to prioritize where automation, supplier consolidation, or dual-sourcing deliver the greatest operational benefit. These combined actions will help leaders preserve product quality while managing the evolving economic and regulatory landscape.

Rely on a mixed-methods research approach combining technical literature review, expert interviews, supplier documentation, and validation through real-world case studies

The research methodology underpinning this executive summary integrates primary and secondary evidence with expert validation to ensure robustness and relevance. First, a structured review of technical literature, regulatory guidance, and product specifications established the foundational understanding of consumables and testing technologies, including the functional distinctions among chromatography media, filtration types, single-use assemblies, and analytical platforms. Second, targeted interviews with senior quality leaders, procurement specialists, and laboratory directors provided real-world perspectives on supplier selection criteria, testing bottlenecks, and responses to tariff-related supply disruptions. These conversations were supplemented by supplier product documentation and publicly available regulatory communications to triangulate claims about performance characteristics and compliance approaches.

Finally, synthesized findings were validated through cross-comparison of method transfer case studies and vendor qualification protocols to ensure practical applicability. Throughout the process, emphasis was placed on reproducibility of testing procedures, transparency of supplier quality systems, and the operational implications of regional supply chain constraints. This mixed-methods approach yields insights that are grounded in both technical detail and operational realities, providing a reliable basis for strategic decisions regarding consumables testing in biologics manufacturing.

Summarize the strategic imperative to align testing workflows, supplier qualification, and analytical capabilities to ensure reliable and compliant biologics production

In conclusion, consumables testing in biopharmaceutical manufacturing is a strategic function that influences product quality, operational efficiency, and regulatory success. The interplay of evolving technologies, shifting sourcing geographies, and heightened regulatory scrutiny requires manufacturers to be proactive in qualifying suppliers, investing in analytical capability, and designing resilient supply strategies. By focusing on material compatibility, method robustness, and supplier transparency, organizations can reduce time-to-release, limit batch failures, and maintain regulatory confidence.

Moving forward, companies that integrate advanced analytical platforms with automated data management and that cultivate collaborative supplier relationships will be best positioned to manage cost pressures and mitigate tariff-related risks. Ultimately, the decisions made today about testing workflows, procurement practices, and regional footprint will determine an organization's ability to scale biologics production reliably and compliantly across diverse markets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of single-use sensor technologies for real-time monitoring of critical bioprocess parameters
  • 5.2. Adoption of AI-driven predictive quality analytics in consumable performance validation
  • 5.3. Implementation of next-generation sterility testing using rapid microbial detection platforms
  • 5.4. Use of advanced polymeric filters with high binding capacities for monoclonal antibody purification processes
  • 5.5. Standardization of extractables and leachables testing protocols for single-use bioprocess assemblies
  • 5.6. Development of customizable single-use assemblies with inline pressure and conductivity sensors for process control
  • 5.7. Shift towards cloud-based data management platforms for traceability and compliance in consumable testing workflows
  • 5.8. Incorporation of fluorescence-based assays for rapid detection of bioburden in single-use cell culture media bags
  • 5.9. Emphasis on lifecycle sustainability metrics in consumable selection and disposal strategies within bioprocess environments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopharmaceuticals Manufacturing Consumables Testing Market, by Product Type

  • 8.1. Chromatography Media
    • 8.1.1. Affinity Resins
    • 8.1.2. Ion Exchange Resins
    • 8.1.3. Protein A Resins
    • 8.1.4. Size Exclusion Media
  • 8.2. Filtration Consumables
    • 8.2.1. Cartridge Filters
    • 8.2.2. Depth Filters
    • 8.2.3. Membrane Filters
  • 8.3. Sampling Assemblies
  • 8.4. Single-Use Bags And Assemblies
    • 8.4.1. Bioreactor Bags
    • 8.4.2. Mixing Bags
    • 8.4.3. Storage Bags
  • 8.5. Tubing And Connectors

9. Biopharmaceuticals Manufacturing Consumables Testing Market, by Testing Type

  • 9.1. Bioburden Testing
  • 9.2. Endotoxin Testing
  • 9.3. pH Testing
  • 9.4. Sterility Testing
    • 9.4.1. Direct Inoculation Test
    • 9.4.2. Membrane Filtration Test

10. Biopharmaceuticals Manufacturing Consumables Testing Market, by Technology

  • 10.1. ELISA
    • 10.1.1. Competitive ELISA
    • 10.1.2. Indirect ELISA
    • 10.1.3. Sandwich ELISA
  • 10.2. Flow Cytometry
  • 10.3. Mass Spectrometry
  • 10.4. Real-Time PCR

11. Biopharmaceuticals Manufacturing Consumables Testing Market, by Application

  • 11.1. Cell Culture Monitoring
  • 11.2. Protein Purification
    • 11.2.1. Affinity Chromatography
    • 11.2.2. Ion Exchange Chromatography
    • 11.2.3. Size Exclusion Chromatography
  • 11.3. Viral Clearance

12. Biopharmaceuticals Manufacturing Consumables Testing Market, by End User

  • 12.1. Academic And Research Institutes
  • 12.2. Biopharmaceutical Companies
    • 12.2.1. Biosimilar Manufacturers
    • 12.2.2. Large Pharma
    • 12.2.3. Mid-Size Pharma
  • 12.3. Contract Manufacturing Organizations
  • 12.4. Contract Research Organizations

13. Biopharmaceuticals Manufacturing Consumables Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biopharmaceuticals Manufacturing Consumables Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biopharmaceuticals Manufacturing Consumables Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. Danaher Corporation
    • 16.3.3. Merck KGaA
    • 16.3.4. Sartorius AG
    • 16.3.5. Corning Incorporated
    • 16.3.6. Agilent Technologies Inc.
    • 16.3.7. Lonza Group AG
    • 16.3.8. PerkinElmer Inc.
    • 16.3.9. Tecan Group Ltd
    • 16.3.10. Repligen Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TESTING TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TESTING TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CHROMATOGRAPHY MEDIA, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CHROMATOGRAPHY MEDIA, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CHROMATOGRAPHY MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CHROMATOGRAPHY MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CHROMATOGRAPHY MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CHROMATOGRAPHY MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CHROMATOGRAPHY MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CHROMATOGRAPHY MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY RESINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY RESINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY RESINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY RESINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY RESINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY RESINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE RESINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE RESINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE RESINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE RESINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE RESINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE RESINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN A RESINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN A RESINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN A RESINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN A RESINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN A RESINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN A RESINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FILTRATION CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FILTRATION CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FILTRATION CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FILTRATION CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FILTRATION CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FILTRATION CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FILTRATION CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FILTRATION CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CARTRIDGE FILTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CARTRIDGE FILTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CARTRIDGE FILTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CARTRIDGE FILTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CARTRIDGE FILTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CARTRIDGE FILTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DEPTH FILTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DEPTH FILTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DEPTH FILTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DEPTH FILTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DEPTH FILTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DEPTH FILTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SAMPLING ASSEMBLIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SAMPLING ASSEMBLIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SAMPLING ASSEMBLIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SAMPLING ASSEMBLIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SAMPLING ASSEMBLIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SAMPLING ASSEMBLIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SINGLE-USE BAGS AND ASSEMBLIES, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SINGLE-USE BAGS AND ASSEMBLIES, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SINGLE-USE BAGS AND ASSEMBLIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SINGLE-USE BAGS AND ASSEMBLIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SINGLE-USE BAGS AND ASSEMBLIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SINGLE-USE BAGS AND ASSEMBLIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SINGLE-USE BAGS AND ASSEMBLIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SINGLE-USE BAGS AND ASSEMBLIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOREACTOR BAGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOREACTOR BAGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOREACTOR BAGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOREACTOR BAGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOREACTOR BAGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOREACTOR BAGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MIXING BAGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MIXING BAGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MIXING BAGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MIXING BAGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MIXING BAGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MIXING BAGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STORAGE BAGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STORAGE BAGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STORAGE BAGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STORAGE BAGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STORAGE BAGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STORAGE BAGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TUBING AND CONNECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TUBING AND CONNECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TUBING AND CONNECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TUBING AND CONNECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TUBING AND CONNECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TUBING AND CONNECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOBURDEN TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOBURDEN TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOBURDEN TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOBURDEN TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOBURDEN TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOBURDEN TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ENDOTOXIN TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ENDOTOXIN TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ENDOTOXIN TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ENDOTOXIN TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ENDOTOXIN TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ENDOTOXIN TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PH TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PH TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PH TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PH TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PH TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PH TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STERILITY TESTING, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STERILITY TESTING, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STERILITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STERILITY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STERILITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STERILITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STERILITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STERILITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DIRECT INOCULATION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DIRECT INOCULATION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DIRECT INOCULATION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DIRECT INOCULATION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DIRECT INOCULATION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DIRECT INOCULATION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTRATION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTRATION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTRATION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTRATION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTRATION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTRATION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY INDIRECT ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY INDIRECT ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY INDIRECT ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY INDIRECT ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY INDIRECT ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY INDIRECT ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CELL CULTURE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CELL CULTURE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CELL CULTURE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CELL CULTURE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CELL CULTURE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CELL CULTURE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN PURIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN PURIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY VIRAL CLEARANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY VIRAL CLEARANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY VIRAL CLEARANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY VIRAL CLEARANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY VIRAL CLEARANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY VIRAL CLEARANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018